A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs GSK 3036656 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2019 Results published in the Antimicrobial Agents and Chemotherapy
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 03 Aug 2017 Planned End Date changed from 25 Jul 2017 to 4 Aug 2017.